^*This webcast is not endorsed by the conference organizer. The Elsevier Office of Continuing Medical Education is an independent medical education company that provides clinical updates, analysis, and expert perspectives through conference-coverage educational programs.

This conference reporter webcast on bladder cancer is based on a roundtable discussion by three experts. During the webcast they provide an overview of challenges in the management of bladder cancer and summarize and discuss recent data presented during the ASCO-GU 2018 Symposium. The experts examine clinical trial outcomes of immunotherapies for bladder cancer and address the question of how current, novel, and emerging treatment options (when approved) could be implemented in individualized treatment plans to optimize treatment selection and outcomes for patients with bladder cancer.

TARGET AUDIENCE

This activity has been designed to meet the educational needs of a broad audience including oncologists, urologists, pathologists, and other healthcare professionals (HCPs) responsible for the diagnosis, treatment, or management of patients with bladder cancer.

EDUCATIONAL OBJECTIVES

After viewing this activity, participants will be better able to:

• Apply methodology to optimally determine the staging of bladder cancer in individual patients
• Analyze clinical trial data of current, novel, and emerging therapies for the treatment of bladder cancer presented at the ASCO-GU 2018 Symposium
• Apply the above knowledge to develop data-driven, individualized treatment plans to improve treatment selection and outcomes for patients with bladder cancer

FACULTY

	Jonathan E. Rosenberg, MD (Chair) Memorial Sloan Kettering Cancer Center New York, NY, USA
	Arlene O. Siefker-Radtke, MD MD Anderson Cancer Center Houston, TX, USA
	Joaquim Bellmunt, MD, PhD Dana-Farber Cancer Institute Boston, MA, USA IMIM Research Institute Barcelona, Spain

Disclosure of Conflicts of Interest

It is the policy of the Elsevier Office of Continuing Medical Education that all faculty, instructors, and planners disclose any real or apparent conflicts of interest relating to the topics of this educational activity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this Continuing Medical Education activity:

Non-faculty: Sandy Breslow; Alison Kemp; Bernard M. Abrams, MD; Joke Artmanni; Elena Knoche, PhD; Marijke Verhaaf; hereby state that neither they nor their spouse/life partner have had any financial relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Financial Support

This activity has been supported by an independent educational grant from Merck Sharp & Dohme Corp.

Provider Information

Jointly provided by the Elsevier Office of Continuing Medical Education and Ology Medical Education.

CME Credit (Physicians)

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Elsevier Office of Continuing Medical Education and Ology Medical Education. The Elsevier Office of Continuing Medical Education is accredited by the ACCME to provide continuing medical education for physicians.

The Elsevier Office of Continuing Medical Education designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CME INQUIRIES/SPECIAL NEEDS

For all CME inquiries or special needs, please contact elsevierCME@elsevier.com.

Disclosure of Unlabeled Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Elsevier Office of Continuing Medical Education, Miller Medical Communications, LLC, Avanir Pharmaceuticals and Biogen do not recommend the use of any agent outside of the labeled indications.

Disclaimer: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Elsevier Office of Continuing Medical Education, Ology Medical Education, and Merck Sharp & Dohme Corp. do not recommend the use of any agent outside of the labeled indications.